Heart | Page 160 of 208 | SpiritIndia.com

Obesity :: 28% Delhi overweight children need to learn healthy lifestyle

More than 28 percent schoolchildren in Delhi have been found to be overweight or obese with one-fourth of them at a risk of getting diabetes. Thirty schools in three cities – Delhi, Jaipur and Agra – are participating in a major intervention programme by the Diabetes Foundation of India to teach students healthy dietary and lifestyle practices to prevent diseases such as diabetes, obesity and heart disorders.

Diet :: Trans fatty acid contents to be declared on food labels – Australia

Trans fatty acid contents must be declared if a nutrition claim is made in respect of cholesterol or saturated, trans, polyunsaturated or monounsaturated fatty acids; or omega-3, omega-6 or omega-9 fatty acids. Some food manufacturers voluntarily list the amount of trans fatty acids in their products.

Diet :: Australia plans to reduce trans fats in food, fast food

The Parliamentary Secretary to the Minister for Health and Ageing, Christopher Pyne, announced today the establishment of a National Collaboration on Trans Fats that will propose initiatives aimed at reducing the amount of trans fatty acids in food sold in Australia. Mr Pyne said that the National Heart Foundation of Australia, the Dietitians Association of Australia, the Australian Food and Grocery Council and Food Standards Australia New Zealand (FSANZ) would lead the initiative.

Heart Disease :: Two drinks daily help men avoid heart attack

Even healthy men may benefit from a drink or two daily to help lower the risk of heart attack, that can be like other lifestyle interventions such as regular physical activity, weight loss and quitting smoking.

Angelina to adopt Indian baby

While the legal battle goes on for the adoption of an African boy by singer Madonna, Hollywood actress Angelina Jolie who will be in India for a month also plans to adopt an Indian baby to add to her growing international brood.

Health :: Venugopal a best doctor but worst administrator – Ramadoss

Describing AIIMS Director P Venugopal as “one of the best doctors”, his bete noire Health Minister Anbumani Ramadoss has said that not all doctors make good administrators. “Venugopal is one of the best doctors in this country. We all respect him. But he is also one of the worst administrators in this country,” Ramadoss said in an interview to a private news channel.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

Diabetes :: Sanofi-Aventis’s Acomplia, rimonabant obesity pill may treat type 2 diabetes

A new obesity pill that helps to control blood sugar levels could treat patients with type 2 diabetes, researchers say. They found that the Sanofi-Aventis drug Acomplia, which is also known as rimonabant, also reduced risk factors for heart disease in patients with type 2 diabetes who had not responded to standard treatments.

Flu :: Exaggerated expectation of flu, influenza vaccines

“We’ve got an exaggerated expectation of what vaccines can actually do,” said study author Dr. Tom Jefferson, coordinator of the Cochrane Vaccines Field in Rome, Italy. “I’m hoping American and European taxpayers will be alerted and will start asking questions.”

Osteosarcoma :: IDM Pharma’s Junovan, mifamurtide in the treatment of osteosarcoma

IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted an electronic New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Junovan(TM) (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.